The model structure illustrating the five first-line strategies for treating mRCC.

<p>The model structure illustrating the five first-line strategies for treating mRCC.</p

Base-Case Cost Estimates ($, year 2011 values) and Utilities.

*<p>The ranges of costs and utilities were obtained from local charge and literatures, respectively.</p

HR and probabilities of SAEs.

*<p>Probabilities are presented as percentages.</p>#<p>The range is from 90% to 110% of the mean.</p>$<p>We assumed that the probabilities were similar to those in the AVOREN Trial.</p>&<p>We assumed the that probabilities were similar to those in the Gore, M. E. 2010 trial.</p>§<p>Rare data were reported; we assumed that the probability of proteinuria was zero.</p

The cost-effectiveness acceptability curves for the five first-line strategies.

<p>(A) without the SPAP; (B) with the SPAP. The y-axis indicates the probability that a strategy is cost-effective across the willingness to pay per QALY gained (x-axis). The bold vertical dashed line represent the thresholds for China.</p

The parameters of the Weibull curves fitted to the interferon-alfa Kaplan-Meier survival data from four pivotal clinical trials.

<p>The parameters of the Weibull curves fitted to the interferon-alfa Kaplan-Meier survival data from four pivotal clinical trials.</p

The base-case results for the five first-line therapies.

<p>Abbreviations: SPAP, patient assistance program; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; LY, life-year; dominated, another strategy was both more effective and less costly; extended dominated, another strategy achieved more effectiveness at a lower incremental cost-effectiveness ratio.</p>*<p>All future costs and QALYs were discounted at 3%.</p>#<p>Compared with Interleukin-2.</p

The cost-effectiveness of first-line strategies for mRCC patients.

<p>(A) without the SPAP; (B) with the SPAP. The x-axis indicates the discounted lifetime quality-adjusted life-years (QALYs) for each strategy, and the y-axis indicates the total discounted lifetime costs (in US dollars). The oblique line connects interleukin-2 and the most cost-effective strategies; strategies above the straight lines were dominated or extended dominated. In the cost-effective plane, the values of the most incremental cost-effectiveness ratios (ICER) are depicted.</p

The probabilistic results of the incremental cost-effectiveness differences.

<p>The comparisons were conducted between sunitinib and (A) interferon-alfa, (B) bevacizumab plus interferon-alfa, (C) interleukin-2 and (D) interleukin-2 plus interferon-alfa for a cohort of 1,000 mRCC patients with or without the SPAP. The y-axis represents the incremental costs. The x-axis represents the incremental quality-adjusted life years (QALYs) gained. The ellipses surround 95% of the estimates. The dots found below the ICER threshold (the oblique lines) reflect simulations in which the cost per additional QALY gained with sunitinib was below the ICER threshold.</p

The Weibull plots of (A) progression-free survival and (B) overall survival.

<p>The Weibull plots of (A) progression-free survival and (B) overall survival.</p

The cost-effective probabilities of five alternative strategies for 32 Chinese provinces with SPAP.^*

*<p>The probabilities were estimated at threshold of 3×per capita GDP and presented as percentages, SPAP: sunitinib patient assistant program.</p